DiaMedica Therapeutics Financials
| DMAC Stock | USD 5.98 0.27 4.32% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 18.21 | 17.34 |
|
|
Investors should never underestimate DiaMedica Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor DiaMedica Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in DiaMedica Therapeutics.
Net Income |
|
DiaMedica | Select Account or Indicator |
Understanding current and past DiaMedica Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of DiaMedica Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in DiaMedica Therapeutics' assets may result in an increase in income on the income statement.
Please note, the presentation of DiaMedica Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, DiaMedica Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of DiaMedica Therapeutics' management manipulating its earnings.
DiaMedica Therapeutics Stock Summary
DiaMedica Therapeutics competes with Milestone Pharmaceuticals, Seres Therapeutics, Inhibikase Therapeutics, Oncolytics Biotech, and Scpharmaceuticals. DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota. Diamedica Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | CA25253X2077 |
| CUSIP | 25253X207 |
| Location | Minnesota; U.S.A |
| Business Address | 301 Carlson Parkway, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.diamedica.com |
| Phone | 763 496 5454 |
| Currency | USD - US Dollar |
DiaMedica Therapeutics Key Financial Ratios
| Return On Equity | -0.42 | ||||
| EBITDA | (19.31 M) | ||||
| Net Income | (19.38 M) | ||||
| Cash Per Share | 1.45 X | ||||
| Current Ratio | 25.50 X |
DiaMedica Therapeutics Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 28.1M | 45.6M | 34.4M | 54.2M | 62.3M | 65.4M | |
| Other Current Liab | 791K | 917K | 1.3M | 1.8M | 2.0M | 2.1M | |
| Net Debt | (7.3M) | (4.7M) | (4.3M) | (4.1M) | (3.7M) | (3.9M) | |
| Retained Earnings | (68.9M) | (82.5M) | (96.2M) | (115.6M) | (104.0M) | (98.8M) | |
| Accounts Payable | 1.1M | 509K | 734K | 926K | 1.1M | 563.1K | |
| Cash | 7.4M | 4.7M | 4.7M | 4.5M | 5.2M | 3.5M | |
| Net Receivables | 340K | 130K | 82K | 369K | 424.4K | 445.6K | |
| Total Liab | 2.1M | 1.5M | 2.6M | 3.1M | 3.6M | 3.7M | |
| Total Current Assets | 27.9M | 45.4M | 33.8M | 53.7M | 61.7M | 64.8M | |
| Short Term Debt | 130K | 98K | 138K | 83K | 95.5K | 83.9K | |
| Other Current Assets | 74K | 197K | 251K | 411K | 472.7K | 496.3K | |
| Net Tangible Assets | 17.0M | 7.6M | 26.0M | 44.0M | 50.6M | 53.2M | |
| Net Invested Capital | 26.0M | 44.0M | 31.8M | 51.1M | 58.7M | 61.7M | |
| Net Working Capital | 25.9M | 43.9M | 31.7M | 50.9M | 58.5M | 61.4M |
DiaMedica Therapeutics Key Income Statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Interest Expense | 119K | 229K | 82K | 353K | 406.0K | 426.2K | |
| Operating Income | (12.7M) | (13.6M) | (14.0M) | (21.3M) | (19.1M) | (18.2M) | |
| Ebit | (12.3M) | (13.6M) | (14.0M) | (19.3M) | (17.4M) | (16.5M) | |
| Research Development | 8.3M | 8.8M | 7.8M | 13.1M | 15.1M | 15.8M | |
| Ebitda | (12.2M) | (13.6M) | (14.0M) | (19.3M) | (17.4M) | (16.5M) | |
| Income Before Tax | (12.3M) | (13.6M) | (13.6M) | (19.3M) | (17.4M) | (16.5M) | |
| Net Income | (12.3M) | (13.6M) | (13.7M) | (19.4M) | (17.4M) | (16.6M) | |
| Income Tax Expense | 31K | 27K | 28K | 43K | 38.7K | 45.2K | |
| Tax Provision | 80K | 31K | 27K | 28K | 32.2K | 33.6K |
DiaMedica Therapeutics Key Cash Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 3.5M | (2.7M) | 21K | (185K) | (166.5K) | (158.2K) | |
| Free Cash Flow | (9.2M) | (12.3M) | (11.6M) | (18.8M) | (16.9M) | (16.0M) | |
| Other Non Cash Items | 52K | 58K | 53K | (1.2M) | (1.0M) | (985.8K) | |
| Net Income | (12.3M) | (13.6M) | (13.7M) | (19.4M) | (17.4M) | (16.6M) | |
| End Period Cash Flow | 7.4M | 4.7M | 4.7M | 4.5M | 5.2M | 3.5M | |
| Investments | (16.1M) | (20.5M) | 11.5M | (19.7M) | (17.7M) | (16.8M) | |
| Change To Netincome | 1.2M | 1.8M | 1.8M | 1.6M | 1.8M | 1.9M |
DiaMedica Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining DiaMedica Therapeutics's current stock value. Our valuation model uses many indicators to compare DiaMedica Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across DiaMedica Therapeutics competition to find correlations between indicators driving DiaMedica Therapeutics's intrinsic value. More Info.DiaMedica Therapeutics is rated # 4 in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, DiaMedica Therapeutics' Return On Equity is projected to increase slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the DiaMedica Therapeutics' earnings, one of the primary drivers of an investment's value.DiaMedica Therapeutics Systematic Risk
DiaMedica Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. DiaMedica Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on DiaMedica Therapeutics correlated with the market. If Beta is less than 0 DiaMedica Therapeutics generally moves in the opposite direction as compared to the market. If DiaMedica Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one DiaMedica Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of DiaMedica Therapeutics is generally in the same direction as the market. If Beta > 1 DiaMedica Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
DiaMedica Therapeutics Thematic Clasifications
DiaMedica Therapeutics is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
| Pharmaceutical Products | View |
Today, most investors in DiaMedica Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various DiaMedica Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of DiaMedica Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
DiaMedica Therapeutics February 25, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of DiaMedica Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of DiaMedica Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of DiaMedica Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing DiaMedica Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build DiaMedica Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 4.26 | |||
| Information Ratio | 0.1431 | |||
| Maximum Drawdown | 47.69 | |||
| Value At Risk | (5.65) | |||
| Potential Upside | 8.64 |
Complementary Tools for DiaMedica Stock analysis
When running DiaMedica Therapeutics' price analysis, check to measure DiaMedica Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DiaMedica Therapeutics is operating at the current time. Most of DiaMedica Therapeutics' value examination focuses on studying past and present price action to predict the probability of DiaMedica Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DiaMedica Therapeutics' price. Additionally, you may evaluate how the addition of DiaMedica Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |